Press Releases

Date	Title
Mar 21, 2024	Chimerix Appoints Marc D. Kozin to Board of Directors Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience DURHAM, N.C. , March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
Feb 29, 2024	Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update – ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – – $204 Million in Cash and Equivalents at December 31, 2023 – – Conference Call at 8:30 a.m.
Feb 27, 2024	Chimerix to Present at TD Cowen 44th Annual Health Care Conference DURHAM, N.C. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole , Chief Executive Officer, will
Feb 22, 2024	Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 DURHAM, N.C. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on

Oncology